Balchem Corp BCPC
We take great care to ensure that the data presented and summarized in this overview for BALCHEM CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BCPC
View all-
Black Rock Inc. New York, NY4.9MShares$769 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.89MShares$610 Million0.01% of portfolio
-
Conestoga Capital Advisors, LLC1.27MShares$200 Million3.07% of portfolio
-
State Street Corp Boston, MA1.2MShares$188 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.08MShares$169 Million0.91% of portfolio
-
Geode Capital Management, LLC Boston, MA996KShares$156 Million0.01% of portfolio
-
Geneva Capital Management LLC988KShares$155 Million2.58% of portfolio
-
Morgan Stanley New York, NY906KShares$142 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX579KShares$90.8 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY557KShares$87.3 Million0.01% of portfolio
Latest Institutional Activity in BCPC
Top Purchases
Top Sells
About BCPC
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York.
Insider Transactions at BCPC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 04
2025
|
Job Leonard Van Gunsteren SVP and GM, Specialty Products |
SELL
Open market or private sale
|
Direct |
6,000
-21.58%
|
$918,000
$153.44 P/Share
|
|
Dec 04
2025
|
Job Leonard Van Gunsteren SVP and GM, Specialty Products |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+27.98%
|
$360,000
$60.85 P/Share
|
|
Dec 03
2025
|
David B Fischer |
SELL
Open market or private sale
|
Direct |
8,000
-28.77%
|
$1,232,000
$154.03 P/Share
|
|
Dec 03
2025
|
David B Fischer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+17.13%
|
$474,000
$79.33 P/Share
|
|
Nov 11
2025
|
Martin Luther Reid SVP Chief Supply Chain Officer |
SELL
Open market or private sale
|
Direct |
1,200
-13.97%
|
$184,800
$154.44 P/Share
|
|
Oct 31
2025
|
Frederic Boned SVP/GM, Human Nutri. & Health |
SELL
Payment of exercise price or tax liability
|
Direct |
1,085
-16.12%
|
$166,005
$153.39 P/Share
|
|
Oct 20
2025
|
George Graham SVP and Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+50.0%
|
-
|
|
Jul 25
2025
|
Hatsuki Miyata EVP, CLO, & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
483
-7.24%
|
$71,484
$148.82 P/Share
|
|
Feb 13
2025
|
Martin Luther Reid SVP Chief Supply Chain Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,059
-10.97%
|
$172,617
$163.14 P/Share
|
|
Feb 13
2025
|
Martin Luther Reid SVP Chief Supply Chain Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,889
+23.04%
|
-
|
|
Feb 13
2025
|
Job Leonard Van Gunsteren SVP and GM, Specialty Products |
SELL
Payment of exercise price or tax liability
|
Direct |
964
-9.26%
|
$157,132
$163.14 P/Share
|
|
Feb 13
2025
|
Job Leonard Van Gunsteren SVP and GM, Specialty Products |
BUY
Grant, award, or other acquisition
|
Direct |
1,718
+14.17%
|
-
|
|
Feb 13
2025
|
Michael Brent Tignor SVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,156
-11.25%
|
$188,428
$163.14 P/Share
|
|
Feb 13
2025
|
Michael Brent Tignor SVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,207
+17.68%
|
-
|
|
Feb 13
2025
|
Theodore L Harris Chairman, President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,442
-12.63%
|
$1,865,046
$163.14 P/Share
|
|
Feb 13
2025
|
Theodore L Harris Chairman, President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
22,364
+19.8%
|
-
|
|
Feb 13
2025
|
Michael Robert Sestrick SVP & Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,045
-18.0%
|
$170,335
$163.14 P/Share
|
|
Feb 13
2025
|
Michael Robert Sestrick SVP & Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,016
+25.77%
|
-
|
|
Feb 13
2025
|
Carl Martin Bengtsson EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,781
-10.71%
|
$453,303
$163.14 P/Share
|
|
Feb 13
2025
|
Carl Martin Bengtsson EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,432
+17.3%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 62.7K shares |
|---|---|
| Exercise of conversion of derivative security | 12K shares |
| Open market or private sale | 15.2K shares |
|---|---|
| Payment of exercise price or tax liability | 26.5K shares |